Miami Nobel laureate gets funding for pharma company

Biscayne Pharmaceuticals, a company that uses the discoveries of Miami Nobel Prize-winner Andrew Schally, announced it has received $1.5 million in financing to develop growth hormone-releasing hormone (GHRH) drugs.

Schally, the Distinguished Leonard M. Miller Professor of Pathology & Professor of Hematology and Oncology at the University of Miami Miller School of Medicine, is working with Joshua M. Hare, a Biscayne co-founder who is the Louis Lemberg Professor of Medicine in the University of Miami Health System, to develop the GHRH technology for coronary heart disease.

The financing was led by the Reich Group, a Miami Beach investment firm. Managing partner Samuel Reich, formerly with Acuity Pharmaceuticals and OPKO Health, is becoming Biscayne’s chief executive and chairman of the board.

Biscayne’s technology is licensed from the University of Miami, the company said in a press release.

Read more Healthcare Reform stories from the Miami Herald

Miami Herald

Join the

The Miami Herald is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere on the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

The Miami Herald uses Facebook's commenting system. You need to log in with a Facebook account in order to comment. If you have questions about commenting with your Facebook account, click here.

Have a news tip? You can send it anonymously. Click here to send us your tip - or - consider joining the Public Insight Network and become a source for The Miami Herald and el Nuevo Herald.

Hide Comments

This affects comments on all stories.

Cancel OK

  • Marketplace

Today's Circulars

  • Quick Job Search

Enter Keyword(s) Enter City Select a State Select a Category